Progyny (NASDAQ:PGNY) vs. Zicix (OTCMKTS:ZICXD) Head to Head Review

Zicix (OTCMKTS:ZICXD) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Institutional & Insider Ownership

94.9% of Progyny shares are held by institutional investors. 9.4% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Zicix and Progyny, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zicix	0	0	0	0	0.00
Progyny	0	4	6	1	2.73

Progyny has a consensus price target of $27.50, indicating a potential upside of 6.59%. Given Progyny’s stronger consensus rating and higher possible upside, analysts plainly believe Progyny is more favorable than Zicix.

Earnings and Valuation

This table compares Zicix and Progyny”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zicix	N/A	N/A	N/A	($100.14)	-0.02
Progyny	$1.17 billion	1.91	$54.34 million	$0.63	40.95

Progyny has higher revenue and earnings than Zicix. Zicix is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Zicix has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Progyny has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Profitability

This table compares Zicix and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zicix	N/A	N/A	N/A
Progyny	4.46%	10.71%	7.27%

Summary

Progyny beats Zicix on 13 of the 13 factors compared between the two stocks.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.